Different Frequency and Clinical Role for MTAP Loss in Pleural and Peritoneal Mesothelioma

Abstract

The objective of this study was to analyze the expression and prognostic role of methylthioadenosine phosphorylase (MTAP) in mesothelioma. MTAP protein expression by immunohistochemistry was analyzed in 113 mesotheliomas (60 pleural and 53 peritoneal), consisting of 36 effusions and 77 surgical specimens. MTAP expression was fully lost in 38 tumors and partially lost in 8 tumors. Loss of expression was significantly more common in effusions compared with biopsies/surgical resection specimens (20/36 vs. 26/77; P=0.017), and in pleural compared with peritoneal mesotheliomas (35/60 vs. 11/53; P<0.001). MTAP performed less robustly than BAP1 in comparative analysis of 57 tumors previously analyzed for expression of the latter protein (46 vs. 25 cases with loss of expression). In survival analysis for 69 patients with partial clinical data, male gender was significantly associated with shorter overall survival (OS; P=0.042), whereas loss of MTAP was associated with a trend for shorter OS (P=0.058), with no prognostic role for patient age (P=0.379) or anatomic site (P=0.381). The association between loss of MTAP and poor OS became significant when survival analysis was limited to patients with pleural mesothelioma (P=0.018). In conclusion, loss of MTAP expression is more frequent in pleural compared with peritoneal mesothelioma and has limited diagnostic relevance at the latter anatomic site. More frequent loss in effusion specimens suggests a role for this marker in effusion cytology. MTAP loss in pleural mesothelioma is associated with poor survival.